How Foundation Models in drug discovery could help cure neglected diseases

The Master Detective

Imagine you are a detective trying to solve a mystery, but someone has hidden almost all the clues. You only have a single footprint and half a fingerprint. A rookie detective would be completely stuck. But what if you brought in a master detective who had already memorised every single case file in history? Because this expert has seen millions of patterns before, they can fill in the blanks. They know that if a footprint is a certain depth, then the suspect has a certain weight. If they see a specific type of mud, then they know exactly which riverbank it came from. They do not need a hundred clues. They only need one or two.

This is exactly the problem scientists face when trying to find medicines for rare or neglected diseases. There is simply not enough data. Traditional methods hit a brick wall.

Foundation Models in drug discovery

Enter artificial intelligence. Specifically, a new review looks at the role of Foundation Models in drug discovery. These are massive computer programmes trained on huge amounts of general information. Think of them like that master detective. Instead of reading case files, they read chemical structures, biological data, and medical texts. They learn the basic rules of biology and chemistry.

If you show them a neglected disease with very little specific data, then they can use their broad background knowledge to suggest a new medicine. They connect the dots that human researchers might miss. The foundation model does the same thing with molecules that the detective does with clues. If it sees a protein with a specific shape, it knows what kind of chemical key might fit into it, even if it has never seen that exact protein before.

How the process works

How does this happen step-by-step? First, the computer programme is fed mixed, messy data from all over the world. It learns the shapes of proteins and how molecules interact. Second, scientists point the model at a specific neglected disease. Third, the model predicts which new chemical compounds might fight the disease. The review measured the recent advances in these techniques, showing how they handle low-data situations.

Levelling the playing field

The researchers suggest that these models could make creating new therapies much fairer. Neglected diseases often affect people in poorer regions. Drug companies usually ignore them because they lack data and funding. This technology might help solve that problem. However, the review notes that simply building the models is not enough. For this to work, scientists must share their data and use the tools responsibly. If researchers collaborate, then these systems may finally offer hope for diseases that the world has forgotten.